# ParadigMM-1B (NCT03287908)

> A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03287908
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Amgen
- Conditions: Relapsed/Refractory Multiple Myeloma
- Interventions: AMG 701; Pomalidomide; Dexamethasone
- Enrollment: 174
- Primary outcome: Number of subjects with dose-limiting toxicities (DLTs)
- Primary outcome: Number of subjects with treatment emergent adverse events (TEAEs)
- Primary outcome: Number of subjects with treatment-related adverse events
- Primary outcome: Number of subjects with disease-related adverse events
- Primary outcome: Number of subjects with clinically-significant changes in vital signs
- Primary outcome: Number of subjects with clinically-significant changes in physical examination measurements
- Primary outcome: Number of subjects with clinically-significant changes in electrocardiogram (ECG) measurements
- Primary outcome: Number of subjects with clinically-significant changes in clinical laboratory tests

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=paradigmm-1b-nct03287908